Pharma Deals Review, Vol 2004, No 51 (2004)

Font Size:  Small  Medium  Large

Structural GenomiX Acquires Troxatyl® from Shire

Business Review Editor

Abstract


Structural GenomiX entered into license agreement with Shire BioChem to acquire worldwide rights for anticancer drug, Troxatyl® (troxocitabine) for treating acute myeloid leukemia and solid tumors.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.